ALUMIS' ENVUDEUCITINIB SHOWS PROMISING EARLY RESULTS IN SKIN CLEARANCE, QUALITY OF LIFE, AND PSORIASIS SYMPTOMS IN TWO PHASE 3 TRIALS, HIGHLIGHTING ITS POTENTIAL AS A TOP ORAL TREATMENT FOR PLAQUE PSORIASIS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ALMS?
Source: moomoo
Clinical Trials Overview: Alumi's recent clinical trials demonstrate early and robust improvements in skin clearance and quality of life for patients with psoriasis.
Potential as Leading Therapy: The trials underscore Alumi's potential to become a leading oral therapy for plaque psoriasis, highlighting its effectiveness in addressing symptoms.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMS
Wall Street analysts forecast ALMS stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.210
Low
32.00
Averages
37.57
High
50.00
Current: 20.210
Low
32.00
Averages
37.57
High
50.00
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Envudeucitinib Shows Strong Efficacy in Psoriasis Trials
- Significant Clinical Response: Envudeucitinib achieved PASI 90 responses of 68.0% and PASI 100 responses of 41.0% by Week 16, demonstrating its robust efficacy in treating moderate-to-severe psoriasis, indicating strong market competitiveness.
- Early Improvement Effects: By Week 4, approximately 75% of patients achieved clear or almost clear scalp psoriasis, and by Week 12, around 50% showed minimal to no disease impact on quality of life, highlighting Envudeucitinib's rapid onset and broad clinical benefits.
- Good Safety Profile: Envudeucitinib's safety through Week 24 was consistent with Phase 2 results, with no serious adverse events reported; the most common side effects were mild and transient, such as headaches and upper respiratory infections, indicating good tolerability.
- Future Development Potential: Alumis plans to submit a New Drug Application to the FDA in the second half of 2026, with Envudeucitinib's sustained clinical responses and safety supporting its potential leading role in psoriasis treatment.
See More
ALUMIS' ENVUDEUCITINIB SHOWS PROMISING EARLY RESULTS IN SKIN CLEARANCE, QUALITY OF LIFE, AND PSORIASIS SYMPTOMS IN TWO PHASE 3 TRIALS, HIGHLIGHTING ITS POTENTIAL AS A TOP ORAL TREATMENT FOR PLAQUE PSORIASIS
Clinical Trials Overview: Alumi's recent clinical trials demonstrate early and robust improvements in skin clearance and quality of life for patients with psoriasis.
Potential as Leading Therapy: The trials underscore Alumi's potential to become a leading oral therapy for plaque psoriasis, highlighting its effectiveness in addressing symptoms.
See More
Alumis Reports 2025 Fiscal Year Financial Results
- Reduced Net Loss: Alumis reported a net loss of $243.3 million for the fiscal year ending December 31, 2025, an improvement from a net loss of $294.2 million in 2024, indicating progress in cost control and operational efficiency despite ongoing financial pressures.
- Revenue Misses Expectations: The fiscal year 2025 revenue of $24.05 million fell short of market expectations by $0.23 million, suggesting challenges in sales and marketing efforts that impacted overall financial performance.
- Strong Cash Reserves: As of December 31, 2025, Alumis held $308.5 million in cash, cash equivalents, and marketable securities, reflecting robust liquidity that supports future R&D and market expansion initiatives.
- Active Financing Activities: Alumis recently priced a $300 million upsized public offering, demonstrating market confidence in its future prospects while providing additional capital to support its research advancements in psoriasis treatment.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: The changes in analyst ratings may lead to short-term volatility in the respective stocks, prompting investors to monitor these shifts closely to optimize their portfolios, especially in the current market environment.
- Impact of Rating Changes: Upgrades or downgrades in ratings typically have a direct effect on stock performance, necessitating that investors stay alert to these changes to timely adjust their investment strategies.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for more in-depth market insights.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics Overview: While specific stock names are not mentioned, such rating changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Investor Focus: For those considering buying ALMS stock, analysts' opinions will serve as a crucial reference point, potentially affecting their buying decisions and overall market sentiment.
- Data Source Note: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions while reminding investors to approach market analyses and recommendations with caution.
See More
Envudeucitinib Shows Strong Efficacy in Psoriasis Trials
- Significant Clinical Response: Envudeucitinib achieved PASI 90 responses of 68.0% and PASI 100 responses of 41.0% by Week 16, demonstrating its robust efficacy in treating moderate-to-severe psoriasis, indicating strong market competitiveness.
- Early Improvement Effects: By Week 4, approximately 75% of patients achieved clear or almost clear scalp psoriasis, and by Week 12, around 50% showed minimal to no disease impact on quality of life, highlighting Envudeucitinib's rapid onset and broad clinical benefits.
- Good Safety Profile: Envudeucitinib's safety through Week 24 was consistent with Phase 2 results, with no serious adverse events reported; the most common side effects were mild and transient, such as headaches and upper respiratory infections, indicating good tolerability.
- Future Development Potential: Alumis plans to submit a New Drug Application to the FDA in the second half of 2026, with Envudeucitinib's sustained clinical responses and safety supporting its potential leading role in psoriasis treatment.
See More
ALUMIS' ENVUDEUCITINIB SHOWS PROMISING EARLY RESULTS IN SKIN CLEARANCE, QUALITY OF LIFE, AND PSORIASIS SYMPTOMS IN TWO PHASE 3 TRIALS, HIGHLIGHTING ITS POTENTIAL AS A TOP ORAL TREATMENT FOR PLAQUE PSORIASIS
Clinical Trials Overview: Alumi's recent clinical trials demonstrate early and robust improvements in skin clearance and quality of life for patients with psoriasis.
Potential as Leading Therapy: The trials underscore Alumi's potential to become a leading oral therapy for plaque psoriasis, highlighting its effectiveness in addressing symptoms.
See More
Alumis Reports 2025 Fiscal Year Financial Results
- Reduced Net Loss: Alumis reported a net loss of $243.3 million for the fiscal year ending December 31, 2025, an improvement from a net loss of $294.2 million in 2024, indicating progress in cost control and operational efficiency despite ongoing financial pressures.
- Revenue Misses Expectations: The fiscal year 2025 revenue of $24.05 million fell short of market expectations by $0.23 million, suggesting challenges in sales and marketing efforts that impacted overall financial performance.
- Strong Cash Reserves: As of December 31, 2025, Alumis held $308.5 million in cash, cash equivalents, and marketable securities, reflecting robust liquidity that supports future R&D and market expansion initiatives.
- Active Financing Activities: Alumis recently priced a $300 million upsized public offering, demonstrating market confidence in its future prospects while providing additional capital to support its research advancements in psoriasis treatment.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: The changes in analyst ratings may lead to short-term volatility in the respective stocks, prompting investors to monitor these shifts closely to optimize their portfolios, especially in the current market environment.
- Impact of Rating Changes: Upgrades or downgrades in ratings typically have a direct effect on stock performance, necessitating that investors stay alert to these changes to timely adjust their investment strategies.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for more in-depth market insights.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics Overview: While specific stock names are not mentioned, such rating changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Investor Focus: For those considering buying ALMS stock, analysts' opinions will serve as a crucial reference point, potentially affecting their buying decisions and overall market sentiment.
- Data Source Note: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions while reminding investors to approach market analyses and recommendations with caution.
See More
